Navigation Links
Lead Therapeutic Candidate for Treatment of Pain from Adynxx, AYX1, Well-Tolerated in Phase 1 Clinical Study
Date:9/5/2012

SAN FRANCISCO, Sept. 5, 2012 /PRNewswire/ -- Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that its lead investigational drug candidate for the prevention of acute and chronic post-operative pain, AYX1, was well-tolerated in a Phase 1 clinical study.

The 30-subject, dose-escalating study evaluated AYX1 in five cohorts of healthy volunteers. AYX1 was well-tolerated at all dose levels, with no serious adverse events reported and no subjects withdrawing from the study.  This positions Adynxx to move AYX1 into a proof-of-concept Phase 2 clinical study later this year. That study will assess the ability of a single administration of AYX1 at the time of surgery to reduce acute pain immediately after surgery, prevent the transition to persistent post-surgical pain, and consequently improve functional recovery. Long-term efficacy of AYX1 after a single administration has been demonstrated in a variety of preclinical pain and functional assessment models.

"We recognize that patients and physicians need new treatment options for post-surgical pain that address its root causes," said Donald Manning, M.D., Ph.D. chief medical officer of Adynxx. "With AYX1, we are aiming to treat post-operative pain as a disease that can be effectively prevented with a single, safe administration at the time of surgery.  Given the urgent need for new pain therapies, we look forward to continuing the advancement of AYX1 and other therapeutics in our pipeline at an aggressive pace."

Added Julien Mamet, Ph.D., founder and chief scientific officer of Adynxx, "We started this company to specifically advance therapeutics that can transform the treatment of pain for patients and physicians. AYX1 has a unique mechanism of action that simultaneously neutralizes multiple molecular mechanisms responsible for the maintenance of pain following surgery. We believe AYX1 will provide a valuable new treatment option to reduce the severity and duration of post-surgical pain suffered by patients."   

In addition to AYX1, Adynxx is advancing a pipeline of therapeutics for treatment of other indications, including intractable neuropathic pain and inflammatory pain syndromes such as chronic lower back pain.

About Adynxx

Adynxx, located in San Francisco, California, is a clinical stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots - preventing the development of pain following surgery or trauma and resolving established chronic pain syndromes.  Adynxx's unique approach is to transform pain management by approaching pain as a disease rather than a symptom. 

Adynxx's lead compound, AYX1, is an investigational drug designed to prevent acute post-surgical pain and the transition to persistent or chronic pain with a single administration at the time of surgery.  Adynxx has completed a Phase 1 clinical trial of AYX1 and plans to initiate a Phase 2 study of AYX1 in Q4 2012.  AYX2, intended to resolve multiple forms of chronic lower back pain, is currently in pre-clinical development along with AYX3, intended to target a range of intractable neuropathic and inflammatory pain syndromes. For more information, visit www.adynxx.com

Media Contact:

David Schull or Ian Stone
Russo Partners
(858) 717-2310
(619) 308-654
david.schull@russopartnersllc.com
ian.stone@russopartnersllc.com

 


'/>"/>
SOURCE Adynxx
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
2. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
3. Echo Therapeutics to Present at the Rodman & Renshaw Annual Global Investment Conference
4. ImmusanT Initiates Clinical Trials of Nexvax2 Therapeutic Vaccine for Celiac Disease
5. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
6. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
8. Global Markets for Animal Therapeutics and Diagnostics
9. Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development
10. Aethlon Medical Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcript
11. Prime Therapeutics named exclusive pharmacy benefit manager for HR Policy Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... , , , WHEN: , , ... , , , LOCATION: , , , Online, with free registration ... PANELISTS:  , , , Frost & Sullivan,s Global Vice President of ... Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... witnessing an exceptional era. Several new demand spaces, such as innovative ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):